The long-term objective of the proposed research is to test the hypothesis that in systemic lupus erythematosus (SLE) there is an increase in the antigen driven autoimmune response through delayed clearance of DNA and nuclear-associated proteins due to an abnormally low C-reactive protein (CRP) response. This hypothesis is based on observations that in the SLE the CRP response during inflammatory episodes related to disease is markedly diminished compared to the degree of inflammation and tissue damage present. The mechanisms responsible for this reduced CRP response are not known. In addition, CRP has been shown to localize in the nuclei of damaged cells and to bind to chromatin. Given the inappropriate CRP-response and the characteristic antibody response to DNA and nuclear proteins in SLE, we, and others, hypothesize that CRP reacts with DNA associated components in damaged tissue and aids in their removal through interactions with the complement system and cells of the phagocytic system. We propose to use human CRP-transgenic (NZB X NZW)F1 mice to test our hypothesis. (NZB X NZW) F1 mice have been utilized as a model for SLE and display a well characterized anti-DNA and anti-nuclear antigen response. Therefore, transgenic (NZB X NZW)F1 mice which have the human CRP gene should be an exceptional tool for studying the effects of CRP on the development of anti-DNA and anti-nuclear antibodies in SLE. Specifically, we plan to determine the effects of human CRP on the development of the lupus like disease of (NZB X NZW)F1 autoimmune mice. We will construct transgenic CB6 mice which express human CRP in an acute phase manner, and then transmit the human CRP on the development of the lupus like disease of (NZB X NZW)F1 autoimmune mice. We will construct transgenic CB6 mice which express human CRP in an acute phase manner, and then transmit the human CRP gene to autoimmune mice through selective breeding. If there is a disease associated CRP response, the development of disease in the CRP transgenic (NZB X NZW)F1 mice will be compared to (NZB X NZW)F1 mice. If there is no significant, disease associated-CRP response in the (NZB X NZW)f1 transgenic mice, we will determine whether these mice have normal CRP expression in response to other stimuli and if the low response is due to some disease related phenomenon. In addition, we will examine the effect of constant expression of CRP on the development of disease in (NZW X NZW)F1 transgenic mice by introducing into the mice DNA constructs of CRP genomic DNA and the mouse metallothionein I enhancer/promoter sequences. The data from the proposed experiments will be an important addition to our knowledge of CRP's role in the development of the autoimmune response, as well as the regulation of CRP's expression in SLE. Finally, these studies will also provide valuable information on regulation of CRP expression within a normal background.

Project Start
Project End
Budget Start
Budget End
Support Year
15
Fiscal Year
1992
Total Cost
Indirect Cost
Name
University of Alabama Birmingham
Department
Type
DUNS #
004514360
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Wu, Jianming; Xie, Fenglong; Qian, Kun et al. (2011) FAS mRNA editing in Human Systemic Lupus Erythematosus. Hum Mutat 32:1268-77
Wang, Feng; Ezell, Scharri J; Zhang, Yong et al. (2010) FBA-TPQ, a novel marine-derived compound as experimental therapy for prostate cancer. Invest New Drugs 28:234-41
Wang, Wei; Rayburn, Elizabeth R; Velu, Sadanandan E et al. (2009) In vitro and in vivo anticancer activity of novel synthetic makaluvamine analogues. Clin Cancer Res 15:3511-8
Wang, Wei; Rayburn, Elizabeth R; Zhao, Yuqing et al. (2009) Novel ginsenosides 25-OH-PPD and 25-OCH3-PPD as experimental therapy for pancreatic cancer: anticancer activity and mechanisms of action. Cancer Lett 278:241-248
Wang, Wei; Rayburn, Elizabeth R; Hang, Jie et al. (2009) Anti-lung cancer effects of novel ginsenoside 25-OCH(3)-PPD. Lung Cancer 65:306-11
Wang, Wei; Rayburn, Elizabeth R; Hao, Miao et al. (2008) Experimental therapy of prostate cancer with novel natural product anti-cancer ginsenosides. Prostate 68:809-19
Annis, Douglas S; Gunderson, Kristin A; Mosher, Deane F (2007) Immunochemical analysis of the structure of the signature domains of thrombospondin-1 and thrombospondin-2 in low calcium concentrations. J Biol Chem 282:27067-75
Rayburn, Elizabeth R; Wang, Wei; Zhang, Ruiwen et al. (2007) Experimental therapy for colon cancer: anti-cancer effects of TLR9 agonism, combination with other therapeutic modalities, and dependence upon p53. Int J Oncol 30:1511-9
Wang, Hui; Rayburn, Elizabeth R; Wang, Wei et al. (2006) Immunomodulatory oligonucleotides as novel therapy for breast cancer: pharmacokinetics, in vitro and in vivo anticancer activity, and potentiation of antibody therapy. Mol Cancer Ther 5:2106-14
Annis, D S; Murphy-Ullrich, J E; Mosher, D F (2006) Function-blocking antithrombospondin-1 monoclonal antibodies. J Thromb Haemost 4:459-68

Showing the most recent 10 out of 145 publications